A Clinical Evaluation of the HYDRA Self Expanding Transcatheter Aortic Valve
NCT ID: NCT02434263
Last Updated: 2021-10-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
165 participants
INTERVENTIONAL
2015-08-13
2025-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All patients will have a clinical follow-up at 30 days, 3months, 6 months and 12 months post implant. The follow-up procedure table is shown in Appendix A.
The patient is enrolled in the study as a subject only upon signature of the informed consent. All subjects will be reviewed by the Principal Investigator prior to undergoing the implant procedure for the Hydra Aortic Heart Valve.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hydra TAVI
Percutaneous Replacement of the Diseased Aortic Valve
Hydra TAVI
Percutaneous Replacement of the Diseased Aortic Valve
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hydra TAVI
Percutaneous Replacement of the Diseased Aortic Valve
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Greater than 55 years of age.
3. Aortic annulus diameter meets the range 18 to 27mm as measured by CT conducted within the past 180 days, or echocardiogram (TEE 3D recommended) if medically contraindicated to CT.
4. Patient has severe degenerative aortic stenosis with echocardiography derived mean gradient \>40mmHg and/or peak velocity greater than 4.0 m/s and/or an initial valve area of \<1.0 cm2.
5. Patient has symptomatic aortic stenosis as demonstrated by NYHA Functional Classification of II or greater.
6. Patient is deemed high operable risk and suitable for TAVI.
7. Patient's predicted operative mortality or serious, irreversible morbidity risk is \<50% at 30 days.
8. Patient has structurally normal cardiac anatomy.
9. Willing and able to comply with all required follow-up evaluation
Exclusion Criteria
2. Patient has carotid artery disease requiring intervention.
3. Patient has evidence of a myocardial infarction (MI) within the past 6 months.
4. Patient has hypertrophic cardiomyopathy.
5. Patient has a native aortic valve that is congenitally uni-cuspid, bicuspid, quadricuspid or non-calcified as seen by echocardiography.
6. Patient has mitral or tricuspid valvular regurgitation (≥ grade III) or moderate to severe mitral stenosis.
7. Patient has aortic root angulation \>70 degrees (horizontal aorta).
8. Patient has aortic root diameter of \< 26 mm or \>36 mm.
9. Patient has a pre-existing prosthetic valve or prosthetic ring in any position.
10. Patient refuses blood transfusion or surgical valve replacement.
11. Patient has resting left ventricular ejection fraction (LVEF) \< 20%.
12. Patient has documented, untreated symptomatic coronary artery disease (CAD) requiring revascularization.
13. Patient has severe basal septal hypertrophy.
14. Patient has had a percutaneous interventional or other invasive cardiac or peripheral procedure ≤ 14 days of the index procedure (does not apply for diagnostic angiography or Angio-CT).
15. Patient has a history of or has active endocarditis.
16. Patient has echocardiographic evidence of intracardiac mass, thrombus, or vegetation.
17. Patient has hemodynamic instability (requiring inotropic support or mechanical heart assistance).
18. Patient is in acute pulmonary edema or requiring intravenous diuretic therapy to stabilize heart failure.
19. Patient with significant pulmonary disease (FEV1 \< 30% as predicted).
20. Patient has significant chronic steroid use as determined and documented by the Principal Investigator.
21. Patient has a known hypersensitivity or contraindication to anticoagulant or antiplatelet medication.
22. Patient has renal insufficiency as evidenced by a serum creatinine \> 3.0 mg/dL (265.5μmol/L) or end-stage renal disease requiring chronic dialysis.
23. Patient's iliofemoral arteries have severe calcification, tortuosity (\>two 90 degree bends), diameter \<6mm, or subject has had an aorto-femoral bypass that preclude safe placement of a 18 French sheath.
24. Patient has blood dyscrasia (leukopenia, acute anemia, thrombocytopenia, bleeding diathesis, or coagulopathy).
25. Patient has a current autoimmune disease that, in the opinion of the Principal Investigator precludes the subject from study participation.
26. Patient has significant aortic disease.
27. Patient has a pre-existing endovascular stent graft in the supra- or infrarenal aorta or pre-existing stent grafts in the iliofemoral arteries.
28. Patient has an active peptic ulcer or has had gastrointestinal (GI) bleeding within the past 90 days prior to procedure
29. Patient has a life expectancy \< 12 months.
30. Patient has other medical, social or psychological conditions that, in the opinion of the Principal Investigator, preclude the subject from study participation.
31. Patient has a known allergy to contrast media, nitinol alloys or bovine tissue.
32. Patient has a history of any cognitive or mental health status that would interfere with study participation.
33. Currently participating in another trial.
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MedPass International
INDUSTRY
Vascular Innovations Co. Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
General Hospital of Athens Ippokration
Athens, , Greece
Prince of Wales Hospital
Hong Kong, , Hong Kong
Vilnius University Hospital Santariškiu Klinikos
Vilnius, , Lithuania
Waikato Hospital
Hamilton, , New Zealand
Instytut Kardiologii im.Prymasa
Warsaw, , Poland
King Chulalongkorn Hospital
Bangkok, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Aidietis A, Srimahachota S, Dabrowski M, Bilkis V, Buddhari W, Cheung GSH, Nair RK, Mussayev AA, Mattummal S, Chandra P, Mahajan AU, Chmielak Z, Govindan SC, Jose J, Hiremath MS, Chandra S, Shetty R, Mohanan S, John JF, Mehrotra S, Sondergaard L. 30-Day and 1-Year Outcomes With HYDRA Self-Expanding Transcatheter Aortic Valve: The Hydra CE Study. JACC Cardiovasc Interv. 2022 Jan 10;15(1):93-104. doi: 10.1016/j.jcin.2021.09.004.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VI-CL-HYDRA-02
Identifier Type: -
Identifier Source: org_study_id